Publications by authors named "Bilian Yao"

Background: Recent evidence has indicated that the O-glycosylated PreS2 domain of the middle HBsAg is a distinguishing characteristic that allows the identification of HBsAg of HBV Dane particles and SVPs. This study's objective was to assess the changes in serum O-glycosylated HBsAg levels in CHB patients undergoing ETV or Peg-IFNα treatment.

Methods: Our retrospective study enrolled 86 patients with genotype C CHB.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness of various tests, including stool and blood markers, in detecting colorectal neoplasia and adenomas.
  • The key findings showed that stool methylated syndecan2 (mSDC2) and fecal occult blood test (FOBT) performed better in detecting colorectal neoplasia, with mSDC2 having 100% sensitivity.
  • However, none of the tests, including CEA, CA125, and CA199, were effective for adenoma detection, and the combination of mSEPT9 and mSDC2 yielded the best results for colorectal neoplasia.
View Article and Find Full Text PDF
Article Synopsis
  • - The study examines how genetic variations linked to Gilbert syndrome (GS), which causes mild bilirubin elevation, impact the outcomes of hepatitis B virus (HBV) infections in patients.
  • - Among the 175 patients studied, those with variant GS had a significantly lower incidence of cirrhosis or hepatocellular carcinoma compared to those with the wild-type gene (13.14% vs. 78.95%).
  • - Results suggest that rarer genetic variants correlate with a better prognosis for HBV infection, indicating the potential therapeutic role of bilirubin elevation in managing the infection.
View Article and Find Full Text PDF

Background And Aims: Monocyte/macrophage-associated CD163 is an indicator of the severity of liver inflammation and cirrhosis, but the difference of soluble CD163 (sCD163) levels in chronic hepatitis B (CHB) patients and hepatitis B surface antigen (HBsAg)-loss patients is unclear. Herein, we aimed to compare the sCD163 levels in CHB patients and HBsAg-loss patients with or without antiviral treatment.

Methods: sCD163 and CD163 expression on monocytes were compared among four groups, healthy subjects, treatment-naïve CHB patients, spontaneous HBsAg-loss patients, and treatment-related HBsAg-loss patients.

View Article and Find Full Text PDF
Article Synopsis
  • Genome-wide studies reveal that the rs12979860 polymorphism in the IL28B gene is linked to treatment responses for chronic hepatitis C.
  • In a study of 259 Chinese Han patients with HCV, the majority had the CC genotype, which was significantly associated with better rates of end-of-treatment response (ETR) and sustained virological response (SVR).
  • This identification of rs12979860 as a predictive marker for treatment outcomes highlights its potential to explain higher SVR rates in this specific population compared to global averages.
View Article and Find Full Text PDF
Article Synopsis
  • The hepatitis C virus F protein can provoke specific CD4(+) T cell responses in patients, indicating its role in immunity.
  • Researchers used HLA-transgenic mouse models and human blood samples to identify specific peptide epitopes of the F protein that activate T cells.
  • This study highlights the importance of the F protein in understanding the immune response and potential complications during chronic hepatitis C infection.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the immune response to the hepatitis C virus (HCV) F protein in patients, finding that 68% of those tested had antibodies against it.
  • It reveals that changes in anti-F antibodies during interferon therapy were significantly different between patients who responded to the treatment and those who did not.
  • The research suggests a potential link between anti-F antibody levels and achieving a sustained virological response (SVR), indicating that the F protein could play a role in HCV treatment outcomes.
View Article and Find Full Text PDF